PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients

L. Richeldi (Southampton, United Kingdom)

Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session: Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session type: Oral Presentation
Number: 3400
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Southampton, United Kingdom). PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. 3400

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009


Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010



Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial
Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs
Year: 2021



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases
Year: 2007


Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021
Year: 2022



Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


The use of modafinil in patients with obstructive apnoea-hyponoea syndrome (OAHS). A randomized, placebo-controlled, double-blind study
Source: Eur Respir J 2001; 18: Suppl. 33, 419s
Year: 2001

Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results
Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation
Year: 2008


Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011